Big data reports for each U.S state are now available from the survey. VisionServe Alliance and The Ohio State University College of Optometry have completed an important national project to comprehensively describe Americans ages 65 and older who are blind or have low vision. The data sets analyzed are from the CDC’s Behavioral Risk [Read More]
Author: Dan Roberts
FDA Approval Brings Long Awaited Hope to Patients With Geographic Atrophy
by Jeff Todd, President + CEO at Prevent Blindness And just like that, the landscape for vision loss and blindness has shifted dramatically! For years, millions of people around the world who are living with an untreatable and potentially blinding condition, along with their care partners, have been waiting with hopeful anticipation for a treatment [Read More]
First Treatment For Geographic Atrophy Approved
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Visual Impairment in Senior Adults Apellis Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved SYFOVRE™ (pegcetacoplan injection) 15mg/0.1mL, the first and only treatment for geographic atrophy (GA) secondary to age-related [Read More]
Important Information About SYFOVRE
Do not receive SYFOVRE if you: have an infection in or around your eye have active swelling in or around your eye that may include pain and redness SYFOVRE can cause serious side effects: Eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment) Call your healthcare provider right away if you have [Read More]
Does VUITY™ Treat AMD?
A new drug called VUITY™ (pilocarpine hydrochloride ophthalmic solution) has recently gained attention as an eye drop that can improve near (close up) vision in individuals over 40. It does not, however, change the condition of the retina. The drug, made by Allergan, works as advertised, but it should not be expected to treat age-related [Read More]